Next Article in Journal
Full Open Access Journals Have Increased Impact Factors
Next Article in Special Issue
Pentavalent Antimonials: New Perspectives for Old Drugs
Previous Article in Journal
Two New Steroidal Saponins from Allium macrostemon Bunge and Their Cytotoxity on Different Cancer Cell Lines
Previous Article in Special Issue
Quantitative Structure ‒ Antiprotozoal Activity Relationships of Sesquiterpene Lactones
Molecules 2009, 14(6), 2256-2272; doi:10.3390/molecules14062256

Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs

1, 1, 1, 2
1, 1, 1, 1, 2
2,*  and 1,*
1 Unidad en Investigación y Desarrollo de Medicamentos, Centro de Investigación en Farmacobiología Aplicada (CIFA), University of Navarra, C/Irunlarrea s/n, 31008 Pamplona, Spain 2 Laboratorio de Química Orgánica, Facultad de Ciencias/Facultad de Química, Universidad de la República, Iguá 4225, 11400 Montevideo, Uruguay
* Authors to whom correspondence should be addressed.
Received: 2 June 2009 / Revised: 15 June 2009 / Accepted: 17 June 2009 / Published: 22 June 2009
Download PDF [149 KB, uploaded 18 June 2014]


Neglected diseases represent a major health problem. It is estimated that one third of the world population is infected with tuberculosis (TB). Besides TB, Chagas disease, affects approximately 20 million people. Quinoxalines display great activities against TB and Chagas. Forty new quinoxaline 1,4-di-N-oxide derivatives have been prepared and tested against M. tuberculosis and T. cruzi. Carboxylic acid quinoxaline 1,4-di-N-oxides (CAQDOs) 5 and 17 showed MIC values on the same order as the reference antituberculosis drug, rifampicin. Meanwhile, CAQDOs 12 and 22 presented IC50 values in the same order as the anti-chagasic drug, nifurtimox.
Keywords: quinoxaline; neglected diseases; Mycobacterium tuberculosis; Trypanosoma cruzi quinoxaline; neglected diseases; Mycobacterium tuberculosis; Trypanosoma cruzi
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Ancizu, S.; Moreno, E.; Torres, E.; Burguete, A.; Pérez-Silanes, S.; Benítez, D.; Villar, R.; Solano, B.; Marín, A.; Aldana, I.; Cerecetto, H.; González, M.; Monge, A. Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs. Molecules 2009, 14, 2256-2272.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert